Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506.
It has been suggested that intercellular adhesion molecule-1 (ICAM-1) may play an important role in the initiation, localization, and perpetuation of autoimmune thyroid diseases (AITD). In an effort to clarify its role, we have investigated the expression of ICAM-1 on thyroid epithelial cells (TEC) of patients with AITD, patients with nontoxic goiter (NTG), and normal subjects (PN) by flow cytometric analysis under basal conditions and after modulation with cytokines, before and after 8 weeks of thyroid tissue xenotransplantation in nude athymic mice (which lyses all passenger lymphocytes), and in severe combined immunodeficient (SCID) mice where these cells survive. Before xenografting, ICAM-1 was expressed on 56% of TEC from Hashimoto's thyroiditis (n = 5), 54% of Graves' disease (n = 6), 15% of NTG (n = 5), and 12% of PN TEC. After the xenografts had been 8 weeks in nude mice, ICAM-1 expression decreased markedly in AITD TEC [from 56% to 10% in Hashimoto's thyroiditis (P < 0.001) and from 54% to 8% in Graves' disease (P < 0.01)], but did not change significantly in NTG or PN. After the xenografts had been 8 weeks in SCID mice, the expression of ICAM-1 was significantly higher on TEC of AITD compared with the same tissue in nude mice. When the SCID mice engrafted with AITD tissue were treated with the anti-CD4+ T (helper) cell agent FK-506, the expression of ICAM-1 was reduced significantly compared with that in the original tissue or that in nontreated mice engrafted with the same tissue. The proportion of TEC that were ICAM-1 positive was up-regulated in all cases by certain cytokines (e.g. interferon-gamma and tumor necrosis factor-alpha applied alone or in combination). We also detected the presence of ICAM-1 in AITD frozen tissues using an immunohistochemical technique. These data suggest a role for ICAM-1 in human AITD. However, the expression of ICAM-1 appears to be a secondary phenomenon in response to the immune assault, rather than a primary event. Our results support the idea that TEC may act as passive captives to immunological events in human AITD.
Arreaza
G
G
Endocrinology Research Laboratory, Wellesley Hospital, University of Toronto, Ontario, Canada.
Yoshikawa
N
N
Mukuta
T
T
Resetkova
E
E
Barsuk
A
A
Nishikawa
M
M
Muallim
C
C
Miller
N
N
Jamieson
C
C
Volpé
R
R
D000818:Animals; D001327:Autoimmune Diseases / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D002478:Cells, Cultured; D016207:Cytokines / Q000627:therapeutic use; D004848:Epithelium / Q000378:metabolism / Q000473:pathology; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D016559:Tacrolimus / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D013961:Thyroid Gland / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D016378:Tissue Transplantation; D014183:Transplantation, Heterologous
D016207:Cytokines; D006684:HLA-DR Antigens; D018799:Intercellular Adhesion Molecule-1; D016559:Tacrolimus